DE69930545D1 - Verfahren zur diagnose und behandlung neurologischer erkrankungen - Google Patents

Verfahren zur diagnose und behandlung neurologischer erkrankungen

Info

Publication number
DE69930545D1
DE69930545D1 DE69930545T DE69930545T DE69930545D1 DE 69930545 D1 DE69930545 D1 DE 69930545D1 DE 69930545 T DE69930545 T DE 69930545T DE 69930545 T DE69930545 T DE 69930545T DE 69930545 D1 DE69930545 D1 DE 69930545D1
Authority
DE
Germany
Prior art keywords
diagnosis
treatment
neurological diseases
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930545T
Other languages
English (en)
Other versions
DE69930545T2 (de
Inventor
Roger Nitsch
Isabell Greeve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Application granted granted Critical
Publication of DE69930545D1 publication Critical patent/DE69930545D1/de
Publication of DE69930545T2 publication Critical patent/DE69930545T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
DE69930545T 1998-11-12 1999-11-12 Verfahren zur diagnose und behandlung neurologischer erkrankungen Expired - Lifetime DE69930545T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98121478A EP1002862A1 (de) 1998-11-12 1998-11-12 Verfahren zur Diagnose oder Behandlung neurologischer Krankheiten
EP98121478 1998-11-12
PCT/EP1999/008744 WO2000029569A1 (en) 1998-11-12 1999-11-12 Methods of diagnosing or treating neurological diseases

Publications (2)

Publication Number Publication Date
DE69930545D1 true DE69930545D1 (de) 2006-05-11
DE69930545T2 DE69930545T2 (de) 2007-03-08

Family

ID=8232965

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930545T Expired - Lifetime DE69930545T2 (de) 1998-11-12 1999-11-12 Verfahren zur diagnose und behandlung neurologischer erkrankungen

Country Status (8)

Country Link
US (2) US20050239169A1 (de)
EP (2) EP1002862A1 (de)
JP (1) JP4663121B2 (de)
AT (1) ATE321135T1 (de)
DE (1) DE69930545T2 (de)
DK (1) DK1129191T3 (de)
ES (1) ES2262352T3 (de)
WO (1) WO2000029569A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107797A4 (de) * 1998-08-27 2002-10-16 Quark Biotech Inc Hypoxie-regulierte gene.
BR0115728A (pt) * 2000-11-28 2003-09-23 Wyeth Corp Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata
EP1398378A4 (de) * 2001-05-31 2005-03-30 Chiba Prefecture In neuroblastom isolierte nukleinsäuren
US20030068636A1 (en) 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
EP1513955A2 (de) * 2002-05-28 2005-03-16 EVOTEC Neurosciences GmbH Diagnostische und therapeutische verwendung von cyp11a1 für neurodegenerative erkrankungen
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
JP7001842B2 (ja) * 2018-04-13 2022-01-20 スン イル コーポレイション 噴射容器及びそのバルブアセンブリ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814157A3 (de) * 1996-06-18 1998-01-07 Smithkline Beecham Corporation Diagnostischer Masker für Varianten von Presenilin Genen, verbunden mit alzheimerischen Krankheit und familiären erwachsenen Einsetzens alzheimerischen Krankheit
EP1107797A4 (de) * 1998-08-27 2002-10-16 Quark Biotech Inc Hypoxie-regulierte gene.

Also Published As

Publication number Publication date
ES2262352T3 (es) 2006-11-16
DK1129191T3 (da) 2006-07-17
ATE321135T1 (de) 2006-04-15
DE69930545T2 (de) 2007-03-08
WO2000029569A1 (en) 2000-05-25
US20050239169A1 (en) 2005-10-27
EP1129191A1 (de) 2001-09-05
JP2002530076A (ja) 2002-09-17
US20080261302A1 (en) 2008-10-23
EP1129191B1 (de) 2006-03-22
EP1002862A1 (de) 2000-05-24
JP4663121B2 (ja) 2011-03-30

Similar Documents

Publication Publication Date Title
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
CY1116682T1 (el) Διπλασιασμος-μυϊκης μαζας σε θηλαστικα
ATE244304T1 (de) Verfahren zur veränderung des essverhaltens, dafür verwendbare verbindungen und dna, die einen hypothalamischen atypischen neuropeptid y/peptid yy rezeptor (y5) kodiert
EP1439230A3 (de) Menschliche transmembranprotein TMP-2 gen
DE3786200D1 (de) Diagnostische verfahren zum nachweis von lymphomen bei menschen.
DE69233736D1 (de) Phosphorylierungsepitope aus dem Tau-Protein zur Diagnose und Behandlung der Alzheimer-Krankheit
ATE355009T1 (de) Auf einem abonnement basierendes biosensorüberwachungsverfahren
TR200103297T2 (tr) Nöral ve renal gelişmenin uyarılması için Ret ligandı (RetL)
DE69929882D1 (de) Verfahren und vorrichtung zur nukleinsäurereinigung
ATE227343T1 (de) Protease und verwandte dns-verbindungen
DE60028544D1 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
DE69930545D1 (de) Verfahren zur diagnose und behandlung neurologischer erkrankungen
DE69729954D1 (de) Identifizierungsverfahren für Substanzen die an das Pyk2 Polypeptid binden
DE69929787D1 (de) Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
PT920501E (pt) Neuritina um neurogene
DE69628702D1 (de) Höckerelektrode für Transistor und Verfahren zur Herstellung
DE69904078T2 (de) Verfahren und vorrichtung zur herstellung von einstückigen gummiraupenketten für traktoren
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69841593D1 (de) Verfahren und Zusammensetzungen für die Diagnose und die Behandlung von Krankheiten, die mit Eisenüberschuss oder Eisenmangel assoziiert sind
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE3885304D1 (de) Zubereitung für zahnbehandlung und verfahren zur herstellung.
DE69532964D1 (de) Neue proteine aus ektoparasitenspeichel und vorrichtung zur sammlung davon
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
ATE312914T1 (de) Rdgb-proteine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1129191

Country of ref document: EP

Representative=s name: VON KREISLER SELTING WERNER, DE